Aardvark Gets FDA Alignment for Prader-Willi Phase 3 Trial
Aardvark Therapeutics lowered the minimum age of eligibility in its Phase 3 HERO trial of ARD-101 for hyperphagia in...
Search results for:
patient recruitment
New Parkinson’s Drug GT-02287 Shows Promising Phase 1b Data
Early interim data from Gain Therapeutics’ Phase 1b study of GT-02287 in Parkinson’s disease point to stability and improvements...
Atea’s New HCV Combo Aims for Best-in-Class Treatment
Atea reported 98% SVR12 (210/215) in the per‑protocol, treatment‑adherent cohort and 95% SVR12 (245/259) in the per‑protocol, regardless‑of‑adherence cohort...
Spur Therapeutics Presents Updated Gaucher Gene Therapy Data
Four adults with type 1 Gaucher disease who received a single low dose of avigbagene parvec (FLT201; 4.5e11 vg/kg)...
Alterity Presents at 2025 Parkinson’s, Movement Disorders
In a randomized, double-blind Phase 2 study of 77 patients with multiple system atrophy (MSA), ATH434 delivered a clinically...
Anavex Drug Delivers Positive Phase 2 Schizophrenia Results
ANAVEX3-71 met its primary endpoint in a placebo-controlled Phase 2 study in adults with schizophrenia on stable antipsychotic therapy,...
Promising VQ-101 Trial Data Offers New Hope for Parkinson’s
VQ-101 delivered more than 70% activation of lysosomal glucocerebrosidase in GBA-Parkinson’s patients after 28 days of once-daily dosing, exceeding...
Vielight Summit: Groundbreaking New Tech For Meditation
No new clinical efficacy endpoints were disclosed. Vielight introduced a meditation-specific protocol within its Neuro Pro photobiomodulation device and...
Silexion Data Shows Powerful 99.7% KRAS Cancer Inhibition
Silexion reported new preclinical data showing its RNAi candidate SIL204 inhibited proliferation by 83.5% to 99.7% across 11 human...
Vivex RESTORE Trial: A New Hope for Degenerative Disc Disease
Vivex Biologics has dosed the first patient in Restore, a randomized, double‑blind, sham‑controlled U.S. trial of VIA Disc NP...